Omeprazole – Canada

Omeprazole – Canada

On March 13, 2017, Apotex filed for leave to appeal the Federal Court of Appeal’s (FCA) decision addressing validity and infringement of AstraZeneca’s Canadian Patent No. 1,292,693 with the Supreme Court of Canada.
The Federal Court on March 16, 2015, held AstraZeneca’s patent valid and infringed by Apotex’s manufacture, sale, and promotion of Apo-Omeprazole capsules. Apotex appealed to FCA.

On appeal, the FCA on January 12, 2017, upheld the Federal Court’s findings on construction, validity and infringement, and affirmed that a patent need only describe a single method or process for making the claimed invention. The FCA also dismissed AstraZeneca’s cross-appeal on punitive damages. 
Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved